Longevity Industrial Complex
mechanismNations & Geopolitics · Biotech & Transhumanism
Billionaires are pouring billions into never dying, while pushing rules to ration ordinary people's healthcare.
Who they are
The cluster of billionaire-funded ventures chasing radical life extension and immortality[1].
What they do
In the engine's read, it's a machine that stretches the powerful's time horizon from decades to centuries. The Calico numbers are now dated: roughly $3.5 billion pledged with AbbVie over the years — and that partnership actually ended in 2025 — plus a 2025 license deal worth $25 million guaranteed and up to $596 million total.
How it works
Over $5 billion has flowed in, including Altos Labs ($3B from Bezos and Milner), Retro Bio ($180M from Altman), Unity Bio ($116M+ from Thiel and Bezos), Alphabet's Calico, and Bryan Johnson's $2M/year regimen, with Thiel saying we should 'escape or transcend evolution'; the engine ties this to a utilitarian bioethics (associated with Emanuel) that rations basic care for the masses.
Why it matters
It points to a two-tier biological future where an elite pursues endless life while everyone else's care gets rationed.
The engine's record — word for word
$5B+ billionaire capital into immortality ventures. Altos Labs $3B (Bezos/Milner), Retro Bio $180M (Altman), Unity Bio $116M+ (Thiel/Bezos), Calico (Alphabet, undisclosed billions). Bryan Johnson Blueprint $2M/yr. Thiel: "we should try to escape or transcend evolution." Material incentive: if you believe you can live forever, you fund any architecture that protects that investment. Time horizon for power expands from decades to centuries. Intersects Complete Lives System (Emanuel): Admin Class pursues immortality while deploying utilitarian bioethics to ration baseline care for the masses. Two-tier biological society. [
Report #188 — Calico ledger dated, verified] Calico launched Sept 18 2013 (Google announcement; Arthur D. Levinson CEO). AbbVie alliance: up to $1.5B pledged 2014, +$1B extension June 2018, +$1B second extension July 2021 — ~$3.5B total potential — and AbbVie ENDED the collaboration in 2025 after 11 years (the exit is part of the record; 'sustained deployment' claims must carry it). June 26 2025: exclusive global license (ex-Greater China) to Mabwell's IL-11 antibody 9MW3811 — $25M upfront + up to $571M milestones = $596M total potential (the smaller figures circulating are milestones-only mislabeled as deal value).
Follow the trail
Walk this on the live map →